Back to search results

Miricorilant for Liver Fat in MASLD

This study is looking at how a medicine called miricorilant affects liver fat in people with MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), also known as NAFLD (Non-alcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis). Researchers want to see if taking 100 mg of miricorilant by mouth once a day for six weeks can change how your liver makes fat. You might be able to join if you are between 18 and 75 years old and have certain liver enzyme levels (AST) or a recent liver biopsy showing specific signs of liver disease. The study aims to enroll 8 participants, but its current recruitment status is unclear.

Study design
This is an open-label study, meaning you and the study team will know you are receiving miricorilant. Approximately 8 participants will receive a single dose of 100 mg of miricorilant daily.
What's involved
Your total participation in the study is expected to last up to 16 weeks, including a 6-week screening period, a 6-week treatment phase, and a 4-week follow-up period.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 4 weeks after the 6-week treatment phase.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06947304

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Active, Not Recruiting
PHASE1Ages 18–75InterventionalTreatment
Corcept Therapeutics
~9 participants
Updated 2026-07-30 on ClinicalTrials.gov
What's tested:Miricorilant

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in fasting hepatic lipogenesis after 6 weeks of treatment
Measured over Baseline to Week 6
+1 more outcome measured

Conditions

Nonalcoholic Steatohepatitis (NASH)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Non-alcoholic Fatty Liver Disease (NAFLD)

Explore related trials

Nonalcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis

NCT06947304

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Missouri

    Columbia, Missourino site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Kavita Juneja, MD · STUDY_DIRECTOR · Corcept Therapeutics

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

AST \> 17 U/L for women and AST \> 20 U/L for men. The AST inclusion criterion does not apply to participants with an eligible historical liver biopsy performed within 12 months of screening showing one of the following:
MRI-PDFF with ≥ 8% steatosis; this assessment must be performed within 4 weeks of the Baseline Visit.
Presence of at least 1 of the following metabolic syndrome characteristics that increase the risk of MASH:
23 kg/m2 in Asians\]), or increased waist circumference ≥ 102 cm (40 in) in men and ≥ 88 cm (35 in) in women (men ≥ 90 cm \[35.4 in\]; women ≥ 80 cm \[31.5 in\] in Asians).

Exclusion

Participation in another clinical trial for MASH or weight loss (e.g., GLP-1 receptor agonists) within the last 3 months.
Participation in any other clinical trial within the last 3 months or 5 half-lives of the treatment, whichever is longer.
Women who are pregnant, planning to become pregnant, or lactating.
BMI \< 18 kg/m² or \> 45 kg/m².
Significant alcohol consumption exceeding 20 g/day for women or 30 g/day for men within 1 year prior to screening.
Positive urine drug screen for amphetamines, cocaine, opiates, or cannabinoids.
Known or suspected cirrhosis or signs of hepatic decompensation.
Other chronic liver diseases such as hepatitis B or C, autoimmune hepatitis, primary biliary cholangitis, or Wilson's disease.
History of myocardial infarction, unstable angina, or stroke within 3 months prior to screening.
Uncontrolled hypertension (systolic \> 160 mm Hg or diastolic \> 100 mm Hg).
Current use of medications prohibited due to potential drug-drug interactions with study treatment.
Contraindications to magnetic resonance imaging (MRI).

What this trial measures

  • Change in fasting hepatic lipogenesis after 6 weeks of treatmentBaseline to Week 6
  • Change in peak lipogenesis after 6 weeks of treatment.Baseline to Week 6